Research analysts covering NEUTRA.
Recent press releases and 8-K filings for NTRR.
Neutrolis Announces Late-Breaking Oral Presentation of Clinical Results
NTRR
New Projects/Investments
- Neutrolis Inc. will present early evidence for human proof of concept of its exDNASE™ therapeutic platform at the American College of Rheumatology (ACR) Convergence 2025.
- The podium presentation is scheduled for October 29, 2025, from 8:45 AM - 9:00 AM CT.
- The data validates DNASE1L3 as a novel therapeutic approach to degrade and inactivate Neutrophil Extracellular Traps (NETs), which are central drivers of systemic inflammatory disorders.
- This marks an important milestone for Neutrolis, underscoring the potential to create a new class of transformational, disease-modifying therapies for conditions such as lupus and rheumatoid arthritis.
Oct 13, 2025, 7:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more